Sera Prognostics (SERA) AI Stock Analysis

• Market Cap: $97.57M
• Dividend Yield: N/A
• Average Volume (3M): 649.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -44.17%
• EPS Growth: 12.77%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.20
• Shares Outstanding: 36,705,025
• 10 Day Avg. Volume: 1,211,953
• 30 Day Avg. Volume: 649,076
• PEG Ratio: -0.04
• Price to Book (P/B): 0.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 29.07
• Enterprise Value/Gross Profit: 1.14K
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $3.00 ▲(8.30%Upside)

Sera Prognostics faces significant challenges with profitability and valuation, although it has a strong balance sheet and is making strategic moves to improve its market position. Technical indicators show mixed signals, while recent corporate events and earnings call insights suggest a cautious but proactive strategic approach.

Positive Factors

Commercialization Opportunity

The company has a significant opportunity ahead with the commercialization of its PreTRM test.

Guideline Inclusion

Guideline inclusion is a critical mid-term catalyst and SERA plans to publish PRIME with 2-3 additional publications which should enhance PreTRM's profile for guideline inclusion.

Market Cap Potential

The market cap of $150M is considered attractive for investors with a longer-term perspective, given the >$2B US total addressable market and a differentiated test.

Negative Factors

Market Perception

There was nothing in this report that changed analysts' thoughts on the name.

Revenue Traction Timeline

Significant material revenue traction is several years away, suggesting a longer-term investment horizon.

Sera Prognostics Business Overview & Revenue Model

Company Description

Sera Prognostics (SERA) is a biotechnology company focusing on women's health, specifically in the area of maternal and fetal health. The company specializes in developing diagnostic tests that predict and manage pregnancy complications, aiming to improve the health outcomes for mothers and their babies. Sera Prognostics leverages advanced proteomics and bioinformatics technologies to create innovative solutions that provide early and accurate risk assessment for pregnancy-related conditions.

How the Company Makes Money

Sera Prognostics makes money primarily through the sale of its proprietary diagnostic tests to healthcare providers, hospitals, and clinics. These tests are designed to predict the risk of pregnancy complications, thereby enabling healthcare professionals to take proactive measures in managing patient care. The company's revenue model is centered around the commercialization and distribution of its flagship product, the PreTRM Test, which assesses the risk of preterm birth. Additionally, Sera Prognostics may generate revenue through strategic partnerships with pharmaceutical and biotechnology companies, as well as through research collaborations and licensing agreements for its technologies. These partnerships can provide additional financial resources and market access, further supporting the company's growth and innovation in the maternal-fetal health sector.

Sera Prognostics Financial Statement Overview

Summary

Sera Prognostics exhibits revenue growth but is not yet profitable, shown by significant negative net profit margins. The balance sheet is strong with low debt, but negative cash flows and profitability metrics indicate ongoing financial challenges.

Income Statement

Sera Prognostics shows revenue growth with a 49.35% increase in the TTM period, but remains unprofitable with a negative net profit margin of -28685.22%. Gross profit margin improved slightly to 8.70% in the TTM, indicating some operational efficiency. However, the persistent negative EBIT and EBITDA margins suggest ongoing challenges in scaling to profitability.

Balance Sheet

The company's balance sheet reveals a stable financial position with a low debt-to-equity ratio of 0.0009 in the TTM. The equity ratio stands at 80.20%, reflecting a strong capital structure. However, the return on equity remains negative due to continued losses, highlighting challenges in generating shareholder returns.

Cash Flow

Free cash flow is negative, though it has improved slightly by 4.02% in the TTM period. The operating cash flow to net income ratio is negative, indicating that the company struggles to convert its earnings into cash, which could affect liquidity and operational flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	115.00K	77.00K	306.00K	268.00K	82.00K	25.00K
Gross Profit	10.00K	-5.00K	96.00K	75.00K	45.00K	14.00K
EBITDA	-33.41M	-32.04M	-35.29M	-42.91M	-33.60M	-17.11M
Net Income	-32.99M	-32.90M	-36.24M	-44.25M	-36.23M	-21.61M
Balance Sheet
Total Assets	118.18M	72.58M	95.44M	116.33M	147.03M	14.80M
Cash, Cash Equivalents and Short-Term Investments	46.20M	46.24M	49.08M	82.70M	105.11M	13.53M
Total Debt	81.00K	840.00K	1.86M	2.31M	128.00K	8.67M
Total Liabilities	23.40M	24.77M	25.28M	17.39M	8.46M	140.37M
Stockholders Equity	94.78M	47.80M	70.16M	98.94M	138.56M	-125.57M
Cash Flow
Free Cash Flow	-27.13M	-14.24M	-27.32M	-35.40M	-32.94M	-17.02M
Operating Cash Flow	-26.74M	-14.19M	-27.19M	-34.61M	-31.64M	-16.87M
Investing Cash Flow	-27.37M	11.74M	438.00K	5.55M	-82.56M	-149.00K
Financing Cash Flow	55.10M	2.61M	752.00K	5.00K	159.59M	9.16M

Sera Prognostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.77
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SERA, the sentiment is Positive. The current price of 2.77 is above the 20-day moving average (MA) of 1.92, above the 50-day MA of 2.27, and below the 200-day MA of 5.18, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 57.85 is Neutral, neither overbought nor oversold. The STOCH value of 74.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SERA.

Sera Prognostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥343.99B	10.56	-2.88%	2.55%	11.80%	-6.84%
XGN	62 Neutral	$153.02M	―	-117.50%	―	1.78%	22.46%
MDXH	57 Neutral	$113.84M	―	-1552.23%	―	25.46%	21.83%
VNRX	53 Neutral	$79.11M	―	138.92%	―	64.15%	41.65%
SERA	52 Neutral	$97.57M	―	-41.36%	―	-44.17%	12.77%
ACRS	46 Neutral	$159.17M	―	-91.03%	―	-40.09%	-18.67%
BDSX	43 Neutral	$36.68M	―	-1454.41%	―	35.76%	47.48%

Sera Prognostics Corporate Events

Sera Prognostics Elects New Board Members at Annual Meeting

On June 5, 2025, Sera Prognostics held its Annual Meeting of Stockholders, where 66.2% of eligible shares were represented. During the meeting, Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. were elected to the Board of Directors for a three-year term, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sera Prognostics Appoints New Chief Commercial Officer

On May 8, 2025, Sera Prognostics announced the appointment of Lee Anderson as Chief Commercial Officer, marking a strategic move to enhance its commercial expansion and innovation. Anderson, with over 30 years of experience in the healthcare sector, is expected to drive the adoption and sales of Sera’s PreTRM Test, leveraging his successful track record from previous roles at Genomic Health and Exact Sciences. His leadership is anticipated to strengthen Sera’s market presence and support its mission to transform women’s healthcare.